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Good Research Practices II Task Force Report achieves its stated
objective, to refresh the 2005 Task Force Report with developments
that have taken place over the past 9 years [1,2]. Certain funda-
mental components of the original report remain the same (e.g.,
data should be fully integrated into the trial; incremental analyses
should be reported with appropriate measures of uncertainty based
on an intention-to-treat analysis). However, the authors conveni-
ently highlight in Table 1 several updates that should improve the
quality of the economic evaluations conducted. Despite advances
over the past 9 years, there remain areas in which further research
and more detailed guidance are needed. Below are just a few areas
in which I hope the (future) third Task Force will report that
progress has been made.
As noted by the Task Force, early joint advice meetings with
both regulatory and HTA agencies are now offered in some
jurisdictions. These meetings have the potential for clarifying
the issues in a comprehensive manner and ideally leading to
greater harmonization of the evidentiary needs of the regulators
and reimbursement agencies. With such alignment, the Task
Force could emphasize that the choice of relevant patient
population, comparator and study endpoints would be most
important, in combination with a discussion of how well the
sponsor's plan will meet these needs. Thus, earlier and closer
alignment of the evidence generation plans for regulatory and
reimbursements purposes are needed in the planning process. It
is important to recognize that not all clinical trials lend them-
selves to conducting cost-effectiveness evaluations (either within
the study period or thru extrapolation beyond the time horizon of
the study). In these cases, clinical trials may still provide an
opportunity to collect data that will inform a future cost-effec-
tiveness model. Regardless of the intended purpose of the trial,
there must be a shared, early understanding of the research
objectives (both clinical and economic) to ensure the design
adequately addresses these needs.
Randomized clinical trials (RCTs) commonly enroll patients
across several countries. Because of questions about the general-
izability of economic results and the desire for country-speciﬁc
analyses by decision-makers, the design and analysis of these
multinational RCTs continue to present challenges for the
researcher. The selection of countries and the distribution of
patients across the countries are critical design elements that are
often decided without consideration of their impact on the
economic evaluation. Thus, guidance is needed on how to deter-
mine whether a country should be represented (or not) in a speciﬁc
RCT based on the potential impact of this decision on pricing and
reimbursement. In multinational RCTs, the Task Force recom-
mends the collection of provider-, site- and jurisdiction-speciﬁcial support: The author has no other ﬁnancial relabaseline data, but we need a better understanding of what
measures will be most useful to incorporate into the analysis.
There also remain questions as to how trial-wide data can best be
utilized to obtain country-speciﬁc estimates for participating
countries as well as country-speciﬁc predictions for non-partici-
pating countries. Because decision-makers are most interested in
economic evaluations tailored to their particular setting, additional
research is needed to continue to reﬁne the guidance.
Value of Information (VOI) continues to be touted from a
theoretical basis, but has yet to take hold in practice. The report
notes that VOI analyses should help inform the decision-makers
on how much money they should be willing to spend in order to
reduce uncertainty in the trade-off decisions they must make. In
practice, however, the sponsor of a new technology remains
responsible for providing evidence that supports recommended
spending levels. Thus, it would seem VOI analyses might be best
used to assess how much the sponsor should be willing to spend
to collect additional data from an RCT(s) in order to reduce
uncertainty in the decisions made by HTA agencies. Practical
guidance on how to conduct VOI analyses from this perspective
(to justify collection of key data for reimbursement purposes)
would be quite useful for economic researchers.
For reimbursement needs to be fully integrated into the clinical
trial program, guidance is needed to bring even greater analytic
rigor to trial-based economic assessments. Pre-testing may be
needed during Phase II trials in order to test the viability of
collecting resource utilization or utility measures in the patient
population of interest. If pre-testing occurs, it may also support
VOI calculations used to identify and justify collection of critical
data elements in subsequent trials for reimbursement purposes.
Results from these early trials can also be used in power calcula-
tions to inform decisions on whether to include formal hypotheses
around these measures. Finally, economic analysis plans must
continue to increase in their scope and speciﬁcity. Key subgroups
for reimbursement purposes should be identiﬁed early in the drug
development process (early economic models can be used for this
purpose). Guiding principles for subgroup analyses in trial-based
cost-effectiveness evaluations should be followed [3]. In addition,
if a beyond-trial projection will be made to assess cost-effective-
ness, a pre-speciﬁed analysis plan should describe how it will be
conducted. While plans may need to be adjusted to respond to
unanticipated study ﬁndings, it doesn't negate the value of pre-
speciﬁcation in elevating the scientiﬁc rigor (and shared under-
standing) of the intended economic evaluation.
Although progress has been made since the ﬁrst report was
issued in 2005, economic evaluations are still viewed as being
conducted “alongside” clinical trials, as if an add-on or after
thought to the regulatory objectives. Hopefully, by the time of thetionships to disclose.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 4 5 – 1 4 6146next Task Force report, guidelines will be provided for the
conduct of economic evaluations “based on” clinical trials, where
the regulatory and reimbursement needs are fully merged.
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